Literature DB >> 21346105

Daily multi-micronutrient supplementation during tuberculosis treatment increases weight and grip strength among HIV-uninfected but not HIV-infected patients in Mwanza, Tanzania.

George PrayGod1, Nyagosya Range, Daniel Faurholt-Jepsen, Kidola Jeremiah, Maria Faurholt-Jepsen, Martine G Aabye, Lotte Jensen, Andreas V Jensen, Harleen M S Grewal, Pascal Magnussen, John Changalucha, Aase Bengaard Andersen, Henrik Friis.   

Abstract

Undernutrition is common among tuberculosis (TB) patients. The objective of this study was to assess the effect of multi-micronutrient supplementation during TB treatment on weight, body composition, and handgrip strength. A total of 865 patients with smear-positive (PTB+) or -negative (PTB-) pulmonary TB were randomly allocated to receive a daily biscuit with or without multi-micronutrients for 60 d during the intensive phase of TB treatment. Weight, arm fat area, arm muscle area, and handgrip strength were assessed at baseline and after 2 and 5 mo. At 2 mo, the multi-micronutrient supplementation led to a higher handgrip gain (1.22 kg; 95% CI = 0.50, 1.94; P = 0.001) but had no effects on other outcomes. The effects of multi-micronutrient supplementation were modified by HIV infection (P-interaction = 0.002). Among HIV- patients, multi-micronutrient supplementation increased weight gain by 590 g (95% CI = -40, 1210; P = 0.07) and handgrip strength by 1.6 kg (95% CI = 0.78, 2.47; P < 0.001), whereas among HIV+ patients, it reduced weight gain by 1440 g (95% CI = 290, 2590; P = 0.002) and had no effect on handgrip strength (0.07 kg; 95% CI = -1.30, 1.46; P = 0.91). The reduced weight gain among HIV+ patients receiving multi-micronutrient supplementation seemed to be explained by a higher proportion of patients reporting fever. At 5 mo, the effects on weight were sustained, whereas there was no effect on handgrip strength. In conclusion, multi-micronutrient supplementation given as a biscuit is beneficial among HIV- PTB patients and may be recommended to TB programs. More research is needed to develop an effective supplement for HIV+ PTB patients.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21346105     DOI: 10.3945/jn.110.131672

Source DB:  PubMed          Journal:  J Nutr        ISSN: 0022-3166            Impact factor:   4.798


  21 in total

Review 1.  Nutritional supplements for people being treated for active tuberculosis.

Authors:  Liesl Grobler; Sukrti Nagpal; Thambu D Sudarsanam; David Sinclair
Journal:  Cochrane Database Syst Rev       Date:  2016-06-29

2.  Predictors of body composition changes during tuberculosis treatment in Mwanza, Tanzania.

Authors:  G PrayGod; N Range; D Faurholt-Jepsen; K Jeremiah; M Faurholt-Jepsen; M G Aabye; P Magnussen; J Changalucha; A B Andersen; J C K Wells; H Friis
Journal:  Eur J Clin Nutr       Date:  2015-04-01       Impact factor: 4.016

3.  Beyond drugs: tuberculosis patients in Bangladesh need nutritional support during convalescence.

Authors:  Q S Islam; S M Ahmed; M A Islam; M Kamruzzaman; M Rifat
Journal:  Public Health Action       Date:  2013-06-21

Review 4.  Dietary selenium in adjuvant therapy of viral and bacterial infections.

Authors:  Holger Steinbrenner; Saleh Al-Quraishy; Mohamed A Dkhil; Frank Wunderlich; Helmut Sies
Journal:  Adv Nutr       Date:  2015-01-15       Impact factor: 8.701

5.  Effect of high-dose vs standard-dose multivitamin supplementation at the initiation of HAART on HIV disease progression and mortality in Tanzania: a randomized controlled trial.

Authors:  Sheila Isanaka; Ferdinand Mugusi; Claudia Hawkins; Donna Spiegelman; James Okuma; Said Aboud; Chalamilla Guerino; Wafaie W Fawzi
Journal:  JAMA       Date:  2012-10-17       Impact factor: 56.272

6.  Nutritional supplementation increases rifampin exposure among tuberculosis patients coinfected with HIV.

Authors:  Kidola Jeremiah; Paolo Denti; Emmanuel Chigutsa; Daniel Faurholt-Jepsen; George PrayGod; Nyagosya Range; Sandra Castel; Lubbe Wiesner; Christian Munch Hagen; Michael Christiansen; John Changalucha; Helen McIlleron; Henrik Friis; Aase Bengaard Andersen
Journal:  Antimicrob Agents Chemother       Date:  2014-04-07       Impact factor: 5.191

7.  CD4 lymphocyte dynamics in Tanzanian pulmonary tuberculosis patients with and without HIV co-infection.

Authors:  Aase B Andersen; Nyagosya S Range; John Changalucha; George Praygod; Jeremiah Kidola; Daniel Faurholt-Jepsen; Henrik Krarup; Harleen M S Grewal; Henrik Friis
Journal:  BMC Infect Dis       Date:  2012-03-21       Impact factor: 3.090

8.  Diabetes is a risk factor for pulmonary tuberculosis: a case-control study from Mwanza, Tanzania.

Authors:  Daniel Faurholt-Jepsen; Nyagosya Range; George Praygod; Kidola Jeremiah; Maria Faurholt-Jepsen; Martine Grosos Aabye; John Changalucha; Dirk Lund Christensen; Christian Bressen Pipper; Henrik Krarup; Daniel Rinse Witte; Aase Bengaard Andersen; Henrik Friis
Journal:  PLoS One       Date:  2011-08-30       Impact factor: 3.240

9.  The prevalence of latent Mycobacterium tuberculosis infection based on an interferon-γ release assay: a cross-sectional survey among urban adults in Mwanza, Tanzania.

Authors:  Andreas V Jensen; Lotte Jensen; Daniel Faurholt-Jepsen; Martine G Aabye; George Praygod; Jeremiah Kidola; Maria Faurholt-Jepsen; John Changalucha; Nyagosya Range; Henrik Krarup; Henrik Friis; Aase B Andersen
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

10.  The role of diabetes co-morbidity for tuberculosis treatment outcomes: a prospective cohort study from Mwanza, Tanzania.

Authors:  Daniel Faurholt-Jepsen; Nyagosya Range; George Praygod; Jeremiah Kidola; Maria Faurholt-Jepsen; Martine Grosos Aabye; John Changalucha; Dirk Lund Christensen; Torben Martinussen; Henrik Krarup; Daniel Rinse Witte; Åse Bengård Andersen; Henrik Friis
Journal:  BMC Infect Dis       Date:  2012-07-27       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.